John Cini
Founder bij SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Vermogen: 3 404 $ op 31-03-2024
Profiel
John K.
Cini is the founder of Sonnet BioTherapeutics, Inc. (founded in 2015) and Sonnet BioTherapeutics Holdings, Inc. (founded in 2011).
At Sonnet BioTherapeutics, Inc., he holds the title of Chief Scientific Officer since 2015, and at Sonnet BioTherapeutics Holdings, Inc., he holds the title of Chief Scientific Officer since 2020.
Dr. Cini's former jobs include Executive Director at Medarex, Inc. and Vice President-Discovery & Development Sciences at Outlook Therapeutics, Inc. (2011-2015).
Dr. Cini earned a doctorate degree from the University of North Texas.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
11-12-2023 | 1 830 ( 0.06% ) | 3 404 $ | 31-03-2024 |
Actieve functies van John Cini
Bedrijven | Functie | Begin |
---|---|---|
SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Founder | 01-01-2011 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Founder | 01-01-2015 |
Eerdere bekende functies van John Cini
Bedrijven | Functie | Einde |
---|---|---|
OUTLOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01-04-2015 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Director/Board Member | - |
Opleiding van John Cini
University of North Texas | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
OUTLOOK THERAPEUTICS, INC. | Health Technology |
SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Health Technology |